NASDAQ:PSNL

Personalis Stock Forecast, Price & News

$43.61

+0.56 (+1.30 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$41.59

Now: $43.61▼

$46.07

50-Day Range

$27.53

MA: $36.18▼

$44.00

52-Week Range

$4.27

Now: $43.61▼

$46.80

Volume998,871 shs

Average Volume1.12 million shs

Market Capitalization$1.70 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.87

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. Personalis, Inc. has partnership with Berry Genomics. The company was founded in 2011 and is headquartered in Menlo Park, California.

Overall MarketRank^™

1.29 out of 5 stars

Medical Sector

613th out of 1,557 stocks

Medical Laboratories Industry

9th out of 30 stocks

2.4 Analyst's Opinion

Consensus Rating
Personalis has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.25, Personalis has a forecasted downside of 14.6% from its current price of $43.61.
Amount of Analyst Coverage
Personalis has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.6 Community Rank

Outperform Votes
Personalis has received 80 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Personalis has received 72 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Personalis has received 52.63% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Personalis and other stocks. Vote “Outperform” if you believe PSNL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PSNL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Personalis does not currently pay a dividend.
Dividend Growth
Personalis does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,313,802.00 in company stock.
Percentage Held by Insiders
Only 8.20% of the stock of Personalis is held by insiders.
Percentage Held by Institutions
61.62% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Personalis are expected to grow in the coming year, from ($1.15) to ($1.08) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Personalis is -43.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Personalis is -43.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Personalis has a P/B Ratio of 12.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Medical laboratories

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PSNL

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.personalis.com

Phone650-752-1300

Employees181

Debt

Debt-to-Equity RatioN/A

Current Ratio2.79

Quick Ratio2.64

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$65.21 million

Price / Sales26.04

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.42 per share

Price / Book12.75

Profitability

EPS (Most Recent Fiscal Year)($1.39)

Net Income$-25,080,000.00

Net Margins-43.16%

Return on Equity-31.11%

Return on Assets-20.78%

Miscellaneous

Outstanding Shares38,933,000

Market Cap$1.70 billion

Next Earnings Date3/24/2021 (Estimated)

OptionableNot Optionable

$43.61

+0.56 (+1.30 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive PSNL News and Ratings via Email

Sign-up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.

Personalis (NASDAQ:PSNL) Frequently Asked Questions

How has Personalis' stock price been impacted by Coronavirus?

Personalis' stock was trading at $6.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PSNL stock has increased by 624.4% and is now trading at $43.61.
View which stocks have been most impacted by COVID-19.

Is Personalis a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Personalis stock.
View analyst ratings for Personalis or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Personalis?

Wall Street analysts have given Personalis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Personalis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Personalis' next earnings date?

Personalis is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Personalis.

How were Personalis' earnings last quarter?

Personalis, Inc. (NASDAQ:PSNL) posted its quarterly earnings results on Thursday, November, 5th. The company reported ($0.27) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.29) by $0.02. The firm had revenue of $19.82 million for the quarter, compared to analyst estimates of $19.25 million. Personalis had a negative net margin of 43.16% and a negative return on equity of 31.11%.
View Personalis' earnings history.

What guidance has Personalis issued on next quarter's earnings?

Personalis updated its fourth quarter 2020 After-Hours earnings guidance on Monday, January, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $20.176-20.176 million, compared to the consensus revenue estimate of $19.7 million.

What price target have analysts set for PSNL?

8 brokerages have issued twelve-month price targets for Personalis' shares. Their forecasts range from $24.00 to $50.00. On average, they anticipate Personalis' stock price to reach $37.25 in the next year. This suggests that the stock has a possible downside of 14.6%.
View analysts' price targets for Personalis or view Wall Street analyst' top-rated stocks.

Who are some of Personalis' key competitors?

Some companies that are related to Personalis include Elekta AB (publ) (EKTAY), CareDx (CDNA), Veracyte (VCYT), Burning Rock Biotech (BNR), Genetron (GTH), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), RadNet (RDNT), Renalytix AI (RNLX), DermTech (DMTK), Progenity (PROG), Centogene (CNTG), Exagen (XGN), Enzo Biochem (ENZ) and Celcuity (CELC).
View all of PSNL's competitors.

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and (APHA).

Who are Personalis' key executives?

Personalis' management team includes the following people:

Mr. John Stephen West, Co-Founder, CEO, Pres & Director (Age 63, Pay $785.44k)
Mr. Aaron L. Tachibana, Chief Financial Officer (Age 59, Pay $494.4k)
Dr. Richard Chen M.S., M.D., MS, Chief Scientific Officer (Age 49, Pay $543.75k)
Prof. Russ B. Altman, Co-Founder and Member of Clinical & Scientific Advisory Board
Mr. Euan A. Ashley M.D., Ph.D., FRCP, DPHIL, Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Atul Butte, Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Michael Snyder Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
Ms. Carol J. Tillis, VP of Fin. & Admin.
Mr. Stephen M. Moore J.D., Gen. Counsel
Mr. Michael J. Fitzpatrick, VP of Worldwide Sales

When did Personalis IPO?

(PSNL) raised $100 million in an initial public offering on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Personalis' stock symbol?

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

How do I buy shares of Personalis?

Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Personalis' stock price today?

One share of PSNL stock can currently be purchased for approximately $43.61.

How big of a company is Personalis?

Personalis has a market capitalization of $1.70 billion and generates $65.21 million in revenue each year. The company earns $-25,080,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Personalis employs 181 workers across the globe.

What is Personalis' official website?

The official website for Personalis is www.personalis.com.

How can I contact Personalis?

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here